Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell Lung cancer

BACKGROUND: Several randomized studies have shown that the combination of programmed cell death 1 (PD-1) inhibitor and chemotherapy is efficacious as a treatment for advanced non-small-cell lung cancer (NSCLC). However, in the neoadjuvant setting, there is scarce evidence of the effectiveness and sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Liang, Meng, Qiyi, Tong, Li, Li, Hongxia, Dong, Yujie, Su, Chongyu, Liu, Zhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614263/
https://www.ncbi.nlm.nih.gov/pubmed/36313678
http://dx.doi.org/10.3389/fonc.2022.956755

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614263/
https://www.ncbi.nlm.nih.gov/pubmed/36313678
http://dx.doi.org/10.3389/fonc.2022.956755

Ejemplares similares